University of Thessaly (UTH)
Αξιολόγηση παραγόντων πρόβλεψης της θεραπευτικής απάντησης στα γλυκοκορτικοειδή σε ασθενείς με θυρεοειδική οφθαλμοπάθεια
Abstract
dc:descriptionObjective: To evaluate the safety and efficacy of an individualized steroid regimen in patients with moderate-to-severe Graves’ Orbitopathy (GO) by monitoring clinical and imaging parameters. Secondarily, to assess the combination of clinical and imaging methods for the prediction of the course of GO.Methods: Thirty-nine patients with active, moderate-to-severe GO were enrolled in this study. Patients received the proposed treatment regimen by EUGOGO of 4.5 g intravenous (iv) Methylprednisolone over 12 weeks. At the end of the iv treatment, subjects with persistent active GO (group 1) as assessed by clinical examination and orbital Magnetic Resonance Imaging (MRI) – STIR sequence (short Τ1 inversion recovery), received additional treatment with oral Prednisolone. Those with inactive GO (group 2) received no further treatment. The second section of our study compares the diameter and cross-section area of the 4 recti Extraocular muscles (EOM), as measured by the MRI. The comparison is among 3 groups, 31 patients with moderate-to-severe GO (62 eyes), 24 patients (48 eyes) with Graves Disease (GD) without clinical GO, and a control group of 72 patients (144 eyes) without ophthalmic and thyroid disease.Results: Of the total of 39 patients that completed the study, 21 entered group 1 and 18 group 2. At 12th week, the overall response to iv treatment was 76.9% and Clinical Activity Score (CAS) improvement 84.6%. At 24th week the overall response was 92.3% and CAS improvement 94.9%, without statistically significant difference in CAS and TES (total eye score) scores between the two groups. Recurrence of disease activity occurred in 7.7% and major adverse events in 4.9% of patients. The second section of our study shows that there is a statistically significant difference of the diameter and area of recti EOMs among the three groups.Conclusion: In patients with moderate-to-severe GO, iv steroid treatment, followed by oral, where needed, is an effective regimen with low rates of adverse events and recurrences. STIR MRI is a significant tool in recognizing patients that need additional steroid treatment, and in predicting the course of GO.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsirouki, Theodora
- Τσιρούκη, Θεοδώρα
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/38875